Riverhead Capital Management’s AbbVie ABBV Stock Holding History

Riverhead Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$6.62M	Buy	87,489 +31,500	+56%	+$2.16M	0.24%	97
2019 Q2	$4.07M	Sell	55,989 -1,685	-3%	-$132K	0.15%	184
2019 Q1	$4.65M	Sell	57,674 -49,560	-46%	-$4.05M	0.19%	153
2018 Q4	$9.89M	Sell	107,234 -38,787	-27%	-$3.41M	0.44%	38
2018 Q3	$13.8M	Buy	146,021 +28,410	+24%	+$2.69M	0.5%	33
2018 Q2	$10.9M	Buy	117,611 +10,702	+10%	+$1.05M	0.43%	42
2018 Q1	$10.1M	Buy	106,909 +55,501	+108%	+$6.1M	0.43%	45
2017 Q4	$4.97M	Buy	51,408 +38,119	+287%	+$3.59M	0.21%	129
2017 Q3	$1.18M	Sell	13,289 -1,950	-13%	-$148K	0.06%	359
2017 Q2	$1.1M	Sell	15,239 -380	-2%	-$25.5K	0.05%	366
2017 Q1	$1.02M	Sell	15,619 -3,620	-19%	-$228K	0.06%	363
2016 Q4	$1.21M	Sell	19,239 -2,600	-12%	-$159K	0.07%	314
2016 Q3	$1.38M	Buy	21,839 +19,892	+1,022%	+$1.29M	0.09%	280
2016 Q2	$92K	Sell	1,947 -88,514	-98%	-$5.39M	﹤0.01%	1192
2016 Q1	$5.17M	Sell	90,461 -203,285	-69%	-$11.3M	0.07%	317
2015 Q4	$17.4M	Sell	293,746 -61,770	-17%	-$3.56M	0.25%	101
2015 Q3	$19.3M	Sell	355,516 -107,805	-23%	-$7.02M	0.31%	88
2015 Q2	$31.1M	Sell	463,321 -91,079	-16%	-$5.95M	0.47%	50
2015 Q1	$32.5M	Buy	554,400 +194,005	+54%	+$11.7M	0.49%	48
2014 Q4	$23.6M	Buy	360,395 +983	+0.3%	+$62K	0.36%	80
2014 Q3	$20.8M	Sell	359,412 -78,082	-18%	-$4.33M	0.36%	74
2014 Q2	$24.7M	Buy	437,494 +113,767	+35%	+$5.97M	0.46%	57
2014 Q1	$16.6M	Buy	323,727 +120,087	+59%	+$6.07M	0.36%	80
2013 Q4	$10.8M	Sell	203,640 -163,060	-44%	-$8.01M	0.29%	100
2013 Q3	$16.4M	Buy	366,700 +83,000	+29%	+$3.68M	0.53%	48
2013 Q2	$11.7M	Buy	+283,700	New	+$12.4M	0.39%	68

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Riverhead Capital Management's ABBV Position: Q3 2019 in Review

Riverhead Capital Management increased its AbbVie (ABBV) stake by 56% in Q3 2019, buying an estimated $2.16M and bringing the position to 87,489 shares worth $6.62M. The position accounts for 0.24% of the portfolio, ranked #97.

Riverhead Capital Management first reported a position in ABBV in Q2 2013 and has held it in 26 quarters since. The position peaked at $32.5M in Q1 2015. 2,003 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

Riverhead Capital Management held 87,489 shares of AbbVie worth $6.62M as of Q3 2019.
Riverhead Capital Management bought 31,500 AbbVie shares in Q3 2019, an estimated $2.16M.
AbbVie made up 0.24% of Riverhead Capital Management's portfolio in Q3 2019, its #97 holding.
Riverhead Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 26 quarters since.
Riverhead Capital Management's AbbVie position peaked at $32.5M in Q1 2015.
2,003 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.